X4 Pharmaceuticals, Inc. announced that it has completed enrollment in the ongoing pivotal Phase II clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene.
[X4 Pharmaceuticals, Inc.]
Sorry, but the selected Zotpress account can't be found.
